MD3222F1 - Method of endometrial cancer diagnosis - Google Patents

Method of endometrial cancer diagnosis

Info

Publication number
MD3222F1
MD3222F1 MDA20060093A MD20060093A MD3222F1 MD 3222 F1 MD3222 F1 MD 3222F1 MD A20060093 A MDA20060093 A MD A20060093A MD 20060093 A MD20060093 A MD 20060093A MD 3222 F1 MD3222 F1 MD 3222F1
Authority
MD
Moldova
Prior art keywords
endometrial cancer
diagnosis
endometrial
cancer diagnosis
concentration
Prior art date
Application number
MDA20060093A
Other languages
Romanian (ro)
Other versions
MD3222G2 (en
Inventor
Dumitru Sofroni
Lilian GUTU
Katja Tenner
Anatolie CERNII
Mihail Todiras
Michael Bader
Original Assignee
Institutia Medico-Sanitara Publica Institutul Oncologic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institutia Medico-Sanitara Publica Institutul Oncologic filed Critical Institutia Medico-Sanitara Publica Institutul Oncologic
Priority to MDA20060093A priority Critical patent/MD3222G2/en
Publication of MD3222F1 publication Critical patent/MD3222F1/en
Publication of MD3222G2 publication Critical patent/MD3222G2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Inventia se refera la medicina, in special la oncologie si poate fi utilizata pentru diagnosticul neinvaziv precoce si pentru confirmarea diagnosticului de cancer endometrial. Esenta inventiei constain determinarea concentratiei de ARN mesager al triptofanhidroxilazei-1 in tesuturile endometrial si miometrial, si in cazul cand in tesutul endometrial concentratia este de 2…100 ori mai mare, se stabileste diagnosticul de cancer endometrial. Rezultatul inventiei consta in posibilitatea diagnosticarii precoce diferentiate a cancerului endometrialpentru stabilirea metodei eficiente de tratament pre- si postoperator.The invention relates to medicine, especially oncology and can be used for early noninvasive diagnosis and for confirming the diagnosis of endometrial cancer. The essence of the invention consists in determining the concentration of messenger RNA of tryptophanhydroxylase-1 in the endometrial and myometrial tissues, and if in the endometrial tissue the concentration is 2 ... 100 times higher, the diagnosis of endometrial cancer is established. The result of the invention consists in the possibility of early differential diagnosis of endometrial cancer for establishing the effective method of pre- and post-operative treatment.

MDA20060093A 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis MD3222G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Publications (2)

Publication Number Publication Date
MD3222F1 true MD3222F1 (en) 2007-01-31
MD3222G2 MD3222G2 (en) 2007-08-31

Family

ID=37776647

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Country Status (1)

Country Link
MD (1) MD3222G2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (en) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of differentiated treatment of endometrial cancer
MD492Z (en) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Method for determining the spread of intestinal type gastric cancer

Also Published As

Publication number Publication date
MD3222G2 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
LTPA2016034I1 (en) Bruton tyrosine kinase inhibitors
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
HUP0302332A2 (en) Gene detection method for improving the likelihood of an effective response to an erbb antagoist cancer therapy
NO20064676L (en) Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid
NZ593474A (en) Compositions and methods for treatment of celiac disease
HK1202561A1 (en) Antibody bound to anionic phospholipid and aminophospholipid, therapeutic and imaging uses thereof
MX2011010390A (en) Polymer-agent conjugates, particles, compositions, and related methods of use.
MA29615B1 (en) PREPARATIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EA200900203A1 (en) ELECTORAL MODULATORS OF ANDROGENS RECEPTOR, THEIR ANALOGUES, DERIVATIVES AND APPLICATIONS
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
EA200970953A1 (en) SPECIFIC INHIBITORS PDGFRβ
DE602005026866D1 (en) USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
RS20150135A1 (en) Treatment with anti-vegf antibodies
CO5660287A2 (en) DERIVATIVES OF TETRAHYDROCARBAZOL AND ITS PHARMACEUTICAL USE
EP2987807A3 (en) Antibodies recognising phospho-tau
DE602005018043D1 (en) LIPOSOMAL FORMULATIONS WITH DIHYDROSPHENOMYLININ AND METHOD FOR THEIR USE
EA201001695A1 (en) APPLICATION OF EPOTHILON D FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TAU-PROTEIN
BRPI0908635B8 (en) compound and/or a pharmaceutically acceptable salt thereof and pharmaceutical composition
EP2687235A3 (en) Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics
SE0300098D0 (en) Use of cyclin D1 inhibitors
MA35281B1 (en) Assay and administration of anti-erbb3 antibodies in combination with paclitaxel for the treatment of gynecological cancers
MX2011010911A (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors.
MD3222F1 (en) Method of endometrial cancer diagnosis
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees